Business Wire

Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Nasdaq

New Evidence on SAPIEN 3 Ultra RESILIA Valve Set to Boost EW Stock

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...
Business Wire

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
TCTMD

TCT 160: Edwards Sapien 3 Ultra Resilia Valves Demonstrate Lower Gradients at 1 Year Compared to Sapien 3 Ultra Valves

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...
Nasdaq

CORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves

Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...
Seeking Alpha

Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript

We're going to get started here as we're moving down the medical devices company presentation, fireside chat track at the 46th Annual TD Cowen Healthcare Conference. I'm Josh Jennings from the TD ...